Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cholangiocarcinoma: early-phase trial registry
36 of 61 indexed Cholangiocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #232 of 28,707 conditions by registered trial count.
61 US clinical trials · 36 currently recruiting · #232 of 28,707 conditions by registered trial count
Cholangiocarcinoma: 61 US clinical trials tracked, 36 recruiting.
Cholangiocarcinoma is the subject of 61 registered US clinical trials on ClinicalTrials.gov, 36 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition cholangiocarcinoma
OPEN 36 | RECR 59% | LATE 3 | EARLY 38 | RANK #232 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Meningioma (59% recruiting · 22 trials)
Cholangiocarcinoma lists 36 open slots (59% of 61 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cholangiocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cholangiocarcinoma is recruiting above its size-band peers.
36 of 61 indexed trials (59%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cholangiocarcinoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 6 of 61 trials (9.8%). 46 distinct sponsors appear on at least one study for this condition label.
-
Typical Cholangiocarcinoma enrolment sits around 110 participants.
Median target enrolment is 110 among the 61 trials that report a genuine target (sentinel values excluded). 28 of those (45.9%) plan for fewer than 100 participants.
-
Cholangiocarcinoma research is mostly interventional.
51 interventional and 10 observational studies make up this index (83.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
61 total, page 2 of 2
EchoTip AcuCore Post-Market Clinical Study
Cook Research Incorporated
NCT06358001
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg
NCT04157985
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Incyte Corporation
NCT02924376
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Senhwa Biosciences
NCT02128282
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
RedHill Biopharma Limited
NCT03377179
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
NCT02520141
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT03829436
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
NCT03207347
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
NCT03693807
A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy
Indiana University
NCT03338062
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
National Cancer Institute (NCI)
NCT03801915
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 18 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cholangiocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cholangiocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cholangiocarcinoma page
61 registered trials, 36 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 36 Cholangiocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Cholangiocarcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cholangiocarcinoma condition card totals 61 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.